RT Journal Article
SR Electronic
T1 Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP jnmt.122.264928
DO 10.2967/jnmt.122.264928
A1 Hossein Jadvar
A1 Patick M. Colletti
YR 2023
UL http://tech.snmjournals.org/content/early/2023/01/04/jnmt.122.264928.abstract
AB Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA-11, 18F-DCFPyL) and radiopharmaceutical therapy (177Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR and those conducted at the University of California (Los Angeles and San Francisco) as well as the randomized phase 3 therapy trial VISION have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharnaecutical therapy clinical trials with the beta emitter, 177Lu-PSMA-617, and the alpha emitter, 225Ac-PSMA-617, in prostate cancer.